Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)

S. Serigstad, Christian Ritz*, D. Faurholt-Jepsen, Dagfinn Markussen, Marit H. Ebbesen, Øyvind Kommedal, R. Bjørneklett, L. Heggelund, Tristan W. Clark, C. H. Van Werkhoven, Siri T. Knoop, E. Ulvestad, Harleen M.S. Grewal, CAPNOR study group

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

20 Downloads (Pure)

Abstract

Background: Community-acquired pneumonia (CAP) causes a large burden of disease. Due to difficulties in obtaining representative respiratory samples and insensitive standard microbiological methods, the microbiological aetiology of CAP is difficult to ascertain. With a few exceptions, standard-of-care diagnostics are too slow to influence initial decisions on antimicrobial therapy. The management of CAP is therefore largely based on empirical treatment guidelines. Empiric antimicrobial therapy is often initiated in the primary care setting, affecting diagnostic tests based on conventional bacterial culture in hospitalized patients. Implementing rapid molecular testing may improve both the proportion of positive tests and the time it takes to obtain test results. Both measures are important for initiation of pathogen-targeted antibiotics, involving rapid de-escalation or escalation of treatment, which may improve antimicrobial stewardship and potentially patient outcome. Methods: Patients presenting to the emergency department of Haukeland University Hospital (HUH) in Bergen, Norway, will be screened for inclusion into a pragmatic randomised controlled trial (RCT). Eligible patients with a suspicion of CAP will be included and randomised to receive either standard-of-care methods (standard microbiological testing) or standard-of-care methods in addition to testing by the rapid and comprehensive real-time multiplex PCR panel, the BioFire® FilmArray® Pneumonia Panel plus (FAP plus) (bioMérieux S.A., Marcy-l’Etoile, France). The results of the FAP plus will be communicated directly to the treating staff within ~2 h of sampling. Discussion: We will examine if rapid use of FAP plus panel in hospitalized patients with suspected CAP can improve both the time to and the proportion of patients receiving pathogen-directed treatment, thereby shortening the exposure to unnecessary antibiotics and the length of hospital admission, compared to the standard-of-care arm. The pragmatic design together with broad inclusion criteria and a straightforward intervention could make our results generalizable to other similar centres. Trial registration: ClinicalTrials.govNCT04660084.

Original languageEnglish
Article number622
JournalTrials
Volume23
Issue number1
Number of pages16
ISSN1745-6215
DOIs
Publication statusPublished - 1. Aug 2022

Keywords

  • Antimicrobial treatment
  • Community-acquired pneumonia
  • FilmArray Pneumonia Panel
  • Induced sputum
  • Microbiological testing
  • Molecular testing
  • Rapid diagnostics
  • Respiratory tract infections
  • Syndromic PCR panel
  • Pneumonia/diagnosis
  • Humans
  • Anti-Infective Agents
  • Molecular Diagnostic Techniques
  • Anti-Bacterial Agents/therapeutic use
  • Community-Acquired Infections/diagnosis

Fingerprint

Dive into the research topics of 'Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)'. Together they form a unique fingerprint.

Cite this